BRPI0518582A2 - implante para liberaÇço de medicamento intra-ocular - Google Patents

implante para liberaÇço de medicamento intra-ocular

Info

Publication number
BRPI0518582A2
BRPI0518582A2 BRPI0518582-3A BRPI0518582A BRPI0518582A2 BR PI0518582 A2 BRPI0518582 A2 BR PI0518582A2 BR PI0518582 A BRPI0518582 A BR PI0518582A BR PI0518582 A2 BRPI0518582 A2 BR PI0518582A2
Authority
BR
Brazil
Prior art keywords
implant
opening
end portion
opposite
drug release
Prior art date
Application number
BRPI0518582-3A
Other languages
English (en)
Inventor
Andreas Reiff
Scott M Hampton
Richard Payne
Original Assignee
Therakine Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therakine Corp filed Critical Therakine Corp
Publication of BRPI0518582A2 publication Critical patent/BRPI0518582A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses or corneal implants; Artificial eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

IMPLANTE PARA LIBERAÇAO DE MEDICAMENTO INTRA-OCULAR. Implante para liberação de medicamento intra-ocular para o tratamento de doenças inflamatórias ou degenerativas. Em uma concretização, o implante inclui uma porção de corpo possuindo uma primeira porção de extremidade e uma segunda porção de extremidade oposta e definindo a cavidade com uma primeira abertura na primeira porção de extremidade, e uma segunda abertura oposta na segunda porção de extremidade e um material sólido compreende um depósito de material e uma quantidade efetiva oral de pelo menos um composto terapêutico ou agente. Quando o implante é implantado em um olho de um indivíduo vivo, a quantidade eficaz de pelo menos um composto terapêutico ou agente é liberada ao ambiente do implante através de pelo menos uma da primeira abertura e da segunda abertura oposta em relação ao período de tempo estendido.
BRPI0518582-3A 2004-11-24 2005-11-16 implante para liberaÇço de medicamento intra-ocular BRPI0518582A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63075104P 2004-11-24 2004-11-24
PCT/US2005/041330 WO2006057859A1 (en) 2004-11-24 2005-11-16 An implant for intraocular drug delivery

Publications (1)

Publication Number Publication Date
BRPI0518582A2 true BRPI0518582A2 (pt) 2008-11-25

Family

ID=36498302

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518582-3A BRPI0518582A2 (pt) 2004-11-24 2005-11-16 implante para liberaÇço de medicamento intra-ocular

Country Status (12)

Country Link
US (2) US20060110429A1 (pt)
EP (1) EP1827462A4 (pt)
JP (1) JP2008521489A (pt)
KR (1) KR20080016780A (pt)
CN (1) CN101132800A (pt)
AU (1) AU2005309854A1 (pt)
BR (1) BRPI0518582A2 (pt)
CA (1) CA2588449A1 (pt)
IL (1) IL183424A0 (pt)
MX (1) MX2007006214A (pt)
RU (1) RU2007123604A (pt)
WO (1) WO2006057859A1 (pt)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US7976520B2 (en) * 2004-01-12 2011-07-12 Nulens Ltd. Eye wall anchored fixtures
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
EP1765454B1 (en) 2004-07-02 2016-04-13 Mati Therapeutics Inc. Treatment medium delivery device for the eye
CA2588449A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
SI1933869T1 (sl) * 2005-09-01 2010-02-26 Schering Corp Uporaba IL-23 in IL-17 antagonistov za zdravljenje avtoimunske očesne vnetne bolezni
EP1979023B1 (en) * 2006-01-17 2015-07-22 Transcend Medical, Inc. Glaucoma treatment device
US7964191B2 (en) * 2006-02-02 2011-06-21 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
EP2004172B1 (en) 2006-03-31 2019-03-13 Mati Therapeutics Inc. Drug delivery structures and compositions for nasolacrimal system
EP2026822A4 (en) * 2006-06-12 2012-07-04 Therakine Ltd TOPICAL TREATMENT FOR EYE SURGERY DISEASES
US9474645B2 (en) * 2006-06-21 2016-10-25 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
US20080045911A1 (en) * 2006-06-21 2008-02-21 Borgia Maureen J Punctal plugs for the delivery of active agents
US9173773B2 (en) 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
EP3351211B1 (en) 2006-07-11 2023-09-06 Refocus Group, Inc. Scleral prosthesis for treating presbyopia and other eye disorders
US8911496B2 (en) 2006-07-11 2014-12-16 Refocus Group, Inc. Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods
CL2007002958A1 (es) * 2006-10-12 2008-05-09 Epix Delaware Inc Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
WO2008073295A2 (en) * 2006-12-07 2008-06-19 Surmodics, Inc. Latent stabilization of bioactive agents releasable from implantable medical articles
US20100114309A1 (en) * 2006-12-26 2010-05-06 De Juan Jr Eugene Drug delivery implants for inhibition of optical defects
ES2732555T3 (es) 2007-09-07 2019-11-25 Mati Therapeutics Inc Implantes lagrimales y métodos relacionados
US9011361B2 (en) 2007-09-07 2015-04-21 Mati Therapeutics Inc. Lacrimal implant detection
EP2207529B1 (en) * 2007-09-07 2014-12-31 Mati Therapeutics Inc. Drug cores for sustained release of therapeutic agents
KR20100102646A (ko) 2007-12-11 2010-09-24 가부시키가이샤 사이토파스파인더 카르복스아미드 화합물 및 케모카인 수용체 길항제로서의 이의 용도
WO2009086106A1 (en) * 2007-12-21 2009-07-09 Mount Sinai School Of Medicine Of New York University Use of podocan protein in treating cardiovascular diseases
AU2009204441B2 (en) 2008-01-09 2015-03-05 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
EP2242520A2 (en) * 2008-01-14 2010-10-27 SurModics, Inc. Devices and methods for elution of nucleic acid delivery complexes
WO2009134371A2 (en) 2008-04-30 2009-11-05 Qlt Plug Delivery, Inc. Composite lacrimal insert and related methods
CA2723192A1 (en) * 2008-05-07 2009-11-12 Surmodics, Inc. Delivery of nucleic acid complexes from particles
MX2010012022A (es) 2008-05-09 2011-03-15 Qlt Plug Delivery Inc Suministro de liberacion sostenida de agentes activos para tratar glaucoma e hipertension ocular.
JP5591226B2 (ja) 2008-05-12 2014-09-17 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 眼内薬物送達装置および関連する方法
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
CA2730760A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
WO2010059847A1 (en) * 2008-11-19 2010-05-27 Refocus Group, Inc. Artificial intraocular lens, altered natural crystalline lens, or refilled natural crystalline lens capsule with one or more scleral prostheses for improved performance
AU2010203425B2 (en) * 2009-01-09 2015-04-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of corneal disorders
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
WO2010093945A2 (en) 2009-02-13 2010-08-19 Glaukos Corporation Uveoscleral drug delivery implant and methods for implanting the same
WO2010096822A2 (en) 2009-02-23 2010-08-26 Qlt Plug Delivery, Inc. Lacrimal implants and related methods
JP5937004B2 (ja) 2009-05-18 2016-06-22 ドーズ メディカル コーポレーションＤｏｓｅ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 薬剤溶出眼内インプラント
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2011031553A2 (en) * 2009-08-27 2011-03-17 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
SG187231A1 (en) 2010-07-29 2013-02-28 Eleven Biotherapeutics Inc Chimeric il-1 receptor type i agonists and antagonists
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
JPWO2012157699A1 (ja) * 2011-05-18 2014-07-31 味の素株式会社 動物用免疫賦活剤、それを含む飼料及びその製造方法
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
ES2727203T3 (es) 2011-08-29 2019-10-14 Mati Therapeutics Inc Administración por liberación sostenida de agentes activos para tratar glaucoma e hipertensión ocular
RU2768492C2 (ru) 2011-11-18 2022-03-24 Ридженерон Фармасьютикалз, Инк. Полимерные белковые микрочастицы
US9474715B2 (en) 2011-11-30 2016-10-25 Andreas Voigt Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
KR101969594B1 (ko) * 2012-05-11 2019-04-16 서강대학교산학협력단 안내 약물 전달 임플란트
DK2859015T3 (en) 2012-06-08 2018-06-18 Alkermes Inc LIGANDS MODIFIED BY CIRCULAR MODIFICATION AS AGONISTS AND ANTAGONISTS
CN107693781B (zh) 2013-03-13 2021-11-09 巴扎德制药公司 用于眼部递送的嵌合细胞因子制剂
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
WO2015021303A1 (en) * 2013-08-08 2015-02-12 Loma Linda University Medical Center Systems and methods for the treatment of bladder cancer
TW201609145A (zh) * 2013-12-25 2016-03-16 參天製藥股份有限公司 注射劑及形成緩釋（ｄｅｐｏｔ）之方法
US20150342875A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
FR3028410A1 (fr) 2014-11-18 2016-05-20 Pierre Coulon Implant capsulaire multifonctionnel
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
EP3344301B1 (en) * 2015-09-04 2020-09-02 University of the Witwatersrand, Johannesburg Biodegradable implant
WO2017053686A1 (en) * 2015-09-24 2017-03-30 Massachusetts Eye And Ear Infirmary Drug delivery system and methods of use
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
CA3001346A1 (en) * 2015-10-16 2017-04-20 Regeneron Pharmaceuticals, Inc. Stable protein compositions
JP7183042B2 (ja) * 2016-01-07 2022-12-05 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 眼の免疫炎症性疾患のための治療法
CN105497991B (zh) * 2016-01-07 2018-08-31 北京大学第三医院 聚羟基脂肪酸酯pha在制备治疗青光眼的产品中的应用
US11318043B2 (en) 2016-04-20 2022-05-03 Dose Medical Corporation Bioresorbable ocular drug delivery device
US11523940B2 (en) 2017-03-17 2022-12-13 W. L. Gore & Associates, Inc. Delivery aids for glaucoma shunts
EP3600244A1 (en) * 2017-03-23 2020-02-05 Particle Sciences, Inc. Implantable and removable drug delivery device
IT201700101582A1 (it) * 2017-09-12 2019-03-12 Milano Politecnico Dispositivo per rilascio intraoculare
US12239573B2 (en) * 2018-08-29 2025-03-04 W. L. Gore & Associates, Inc. Drug therapy delivery systems and methods
US11678983B2 (en) 2018-12-12 2023-06-20 W. L. Gore & Associates, Inc. Implantable component with socket
IT201900003597A1 (it) * 2019-03-12 2020-09-12 Milano Politecnico Dispositivo per il rilascio controllato
AU2020394444B2 (en) 2019-11-25 2025-05-29 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
EP4314073A4 (en) 2021-03-24 2025-02-19 Alkermes, Inc. Upar antibodies and fusion proteins with the same
EP4346720A4 (en) 2021-05-28 2025-01-01 Sight Sciences, Inc. INTRAOCULAR DEVICES, SYSTEMS AND METHODS
US20230021788A1 (en) * 2021-07-14 2023-01-26 Acclarent, Inc. Multi-layer drug delivery apparatus
US12527691B2 (en) 2021-11-05 2026-01-20 W. L. Gore & Associates, Inc. Fluid drainage devices, systems, and methods

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3977404A (en) * 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US5269812A (en) * 1986-05-16 1993-12-14 White Thomas C Methods and devices employed in replacement of the corneal endothelium
US5139518A (en) * 1986-05-16 1992-08-18 White Thomas C Methods employed in replacement of the corneal endothelium
US4863457A (en) * 1986-11-24 1989-09-05 Lee David A Drug delivery device
DK0454044T3 (da) * 1990-04-25 1996-04-22 Hoechst Ag Farmakologisk præparat indeholdende polyelektrolytkomplekser på mikropartikelform og mindst et virksomt stof
US5041081A (en) * 1990-05-18 1991-08-20 Odrich Ronald B Ocular implant for controlling glaucoma
US5830508A (en) * 1992-08-06 1998-11-03 Deo Corporation Composition for treating dry eye
US5707643A (en) * 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
US5622965A (en) * 1993-03-12 1997-04-22 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon 4-hydroxy-3-nitro-1,2-dihydroquinolin-2-ones and the use thereof as excitatory amino acid and glycine receptor antagonists
JPH08512056A (ja) * 1993-06-30 1996-12-17 ジェネンテク・インコーポレイテッド リポソームの製造法
US5466233A (en) * 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
ATE355379T1 (de) * 1994-04-26 2006-03-15 Childrens Medical Center Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese
US6107045A (en) * 1994-06-30 2000-08-22 Oklahoma Medical Research Foundation Antibodies to lipoproteins and apolipoproteins and methods of use thereof
US6063396A (en) * 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US5900245A (en) * 1996-03-22 1999-05-04 Focal, Inc. Compliant tissue sealants
US5612027A (en) * 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US5861372A (en) * 1996-02-22 1999-01-19 The Children's Medical Center Corporation Aggregate angiostatin and method of use
US5837240A (en) * 1995-04-28 1998-11-17 Oravax-Merieux Co. Multimeric, recombinant urease vaccine
US5968058A (en) * 1996-03-27 1999-10-19 Optonol Ltd. Device for and method of implanting an intraocular implant
EP0842209B1 (en) * 1995-07-28 2006-10-11 Genzyme Corporation Multiblock biodegradable hydrogels for use as controlled release agents for drugs and tissue treatment agents
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
AR009439A1 (es) * 1996-12-23 2000-04-12 Novartis Ag Un articulo que comprende un sustrato con un recubrimiento polimerico primario que porta grupos reactivos predominantemente en su superficie, unmetodo para preparar dicho articulo, un articulo que posee un recubrimiento de tipo hibrido y una lente de contacto
DE69816980T2 (de) * 1997-03-31 2004-07-22 Alza Corp., Palo Alto Implantierbares diffusionabgabesystem
US6224893B1 (en) * 1997-04-11 2001-05-01 Massachusetts Institute Of Technology Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering
US6638621B2 (en) * 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US6186148B1 (en) * 1998-02-04 2001-02-13 Kiyoshi Okada Prevention of posterior capsular opacification
US6599879B1 (en) * 1998-02-13 2003-07-29 Human Genome Sciences, Inc. Therapeutic uses of keratinocyte growth factor-2
WO1999047253A1 (en) * 1998-03-19 1999-09-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Fabrication of multilayer-coated particles and hollow shells via electrostatic self-assembly of nanocomposite multilayers on decomposable colloidal templates
US7101575B2 (en) * 1998-03-19 2006-09-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
US20020099438A1 (en) * 1998-04-15 2002-07-25 Furst Joseph G. Irradiated stent coating
ES2292250T5 (es) * 1998-07-15 2010-09-14 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Envolventes de polielectrolitos sobre plantillas (templates) biologicas.
EP1098642B1 (en) * 1998-07-27 2007-04-04 Johns Hopkins University Diamino-propanol-compounds for treating ischemia
DE69936212T2 (de) * 1998-09-04 2008-01-24 Scios Inc., Sunnyvale Hydrogelzusammensetzungen mit kontrollierter Freigabe für die Verabreichung von Wachstumsfaktoren
US6630457B1 (en) * 1998-09-18 2003-10-07 Orthogene Llc Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
IT1302534B1 (it) * 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
US6395029B1 (en) * 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
FR2791552B1 (fr) * 1999-04-02 2001-10-19 Georges Baikoff Implant pour la correction de la presbytie des yeux phaques
US6312725B1 (en) * 1999-04-16 2001-11-06 Cohesion Technologies, Inc. Rapid gelling biocompatible polymer composition
WO2000077281A1 (en) * 1999-06-10 2000-12-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Encapsulation of crystals via multilayer coatings
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6204270B1 (en) * 1999-11-12 2001-03-20 Eyal S. Ron Ophthalmic and mucosal preparations
EP1231905B1 (en) * 1999-11-15 2009-04-08 BioCure, Inc. Responsive polymeric hollow particles
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
DE10001172A1 (de) * 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
US20030186386A1 (en) * 2000-02-11 2003-10-02 Hansen Christian Karsten Interleukin 10
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
ATE377404T1 (de) * 2000-05-19 2007-11-15 Michael S Berlin Laserapplikationssystem und methode zur verwendung im auge
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US6458275B1 (en) * 2000-06-05 2002-10-01 Harvard Apparatus, Inc. Multi-well equilibrium dialysis system
ATE404140T1 (de) * 2000-08-30 2008-08-15 Univ Johns Hopkins Vorrichtung zur intraokularen wirkstoffverabreichung
AU2002248284A1 (en) * 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
EP1404295B1 (en) * 2001-01-03 2007-10-10 Bausch & Lomb Incorporated Sustained release drug delivery devices with coated drug cores
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US6849271B2 (en) * 2001-04-27 2005-02-01 Verion, Inc. Microcapsule matrix microspheres, absorption-enhancing pharmaceutical compositions and methods
US20030211464A1 (en) * 2001-05-02 2003-11-13 Charles Pidgeon Method and compositions for drug discovery
JP4531290B2 (ja) * 2001-05-18 2010-08-25 大日本印刷株式会社 保護拡散フィルム、面光源装置及び液晶表示装置
US20040062768A1 (en) * 2001-06-05 2004-04-01 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
JP4677538B2 (ja) * 2001-06-12 2011-04-27 ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン 眼内薬物送達のためのリザーバデバイス
JP2004537401A (ja) * 2001-08-08 2004-12-16 ブラウン ユニバーシティ リサーチ ファウンデーション 疎水性薬物の微粉砕方法
HRP20040406A2 (en) * 2001-11-09 2005-02-28 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
US7090888B2 (en) * 2002-01-18 2006-08-15 Snyder Michael E Sustained release ophthalmological device and method of making and using the same
CA2511484A1 (en) * 2002-12-30 2004-07-22 Angiotech International Ag Silk-containing stent graft
WO2004066980A2 (en) * 2003-01-24 2004-08-12 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US7241455B2 (en) * 2003-04-08 2007-07-10 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing radiation-crosslinked polymer for controlled delivery of a therapeutic agent
US7332470B2 (en) * 2003-04-15 2008-02-19 The Regents Of The University Of California Methods and compositions for treating ocular disease
US6923996B2 (en) * 2003-05-06 2005-08-02 Scimed Life Systems, Inc. Processes for producing polymer coatings for release of therapeutic agent
US7364585B2 (en) * 2003-08-11 2008-04-29 Boston Scientific Scimed, Inc. Medical devices comprising drug-loaded capsules for localized drug delivery
CA2588449A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery

Also Published As

Publication number Publication date
EP1827462A4 (en) 2012-01-04
AU2005309854A1 (en) 2006-06-01
RU2007123604A (ru) 2008-12-27
WO2006057859A1 (en) 2006-06-01
CN101132800A (zh) 2008-02-27
KR20080016780A (ko) 2008-02-22
EP1827462A1 (en) 2007-09-05
CA2588449A1 (en) 2006-06-01
US20060110429A1 (en) 2006-05-25
MX2007006214A (es) 2008-04-16
IL183424A0 (en) 2008-04-13
US20090214619A1 (en) 2009-08-27
JP2008521489A (ja) 2008-06-26

Similar Documents

Publication Publication Date Title
MX2007006214A (es) Un implante para suministro de farmaco intraocular.
BR0306513A (pt) tampão com medicamento
SG170816A1 (en) Drug delivery methods, structures, and compositions for nasolacrimal system
AR026986A1 (es) Implante farmaceutico con contenido de componentes de liberacion inmediata y liberacion sostenida y metodos de administracion
NZ583861A (en) Lacrimal implants with an angled intersection between its sections so as to bias a portion of the body against the tissue surface
BRPI0617325B8 (pt) luva biologicamente compatível
BR0015284A (pt) Formulações de hidrocodona de liberação controlada
BR112012025581A2 (pt) implantes de reservatório de liberação sustentada para distribuição de fármaco intracameral
WO2008079404A3 (en) Pharmaceutical compositions for treatment of parkinson's disease and related disorders
AR063619A1 (es) Dispositivos y metodos para la administraicion de un farmaco oftalmico
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
BRPI0820800A2 (pt) Dispositivo médico implantável para liberação controlada de droga, e, métodos para administração de uma droga na bexiga de um paciente e para tratar a bexiga em um paciente
WO2007109496A3 (en) Devices and methods for targeted nasal phototherapy
WO2005070008A3 (en) Polymer no donor predrug nanofiber coating for medical devices and therapy
NZ606825A (en) Methods and compositions for treating complement-associated disorders
BR0313954A (pt) Composição de cerâmica biocompatìvel, dispositivo médico, método para fabricar uma composição de cerâmica biocompatìvel, implantes médico e ortopédico, material de enchimento dental ou implante dental, veìculo de droga para liberação de droga no corpo de um paciente, uso da composição de cerâmica biocompatìvel, método para gerar calor in vivo no corpo de um paciente para propósitos terapêuticos, e, método terapêutico
AR039947A1 (es) Formulacion farmaceutica que comprende nicotina
EP4371535A3 (en) Ocular implant
WO2006044890A3 (en) Self-fixating implantable scaffolds for the administration of biological or pharmaceutical substances
Papagelopoulos et al. Calcium sulphate delivery system with tobramycin for the treatment of chronic calcaneal osteomyelitis
US20060167408A1 (en) Single-use syringe incorporating a sliding protection sheath for the needle
MX2009005837A (es) Dispositivos medicos para distribucion localizada de farmacos.
BR0215382A (pt) Método e implante intra-esclerótico para o tratamento de glaucoma e presbiopia
BRPI0519022A2 (pt) formaÇço insitu de implante para animais
Park et al. The evaluation of the use of a delayed surgical obturator in dentate maxillectomy patients by considering days elapsed prior to commencement of postoperative oral feeding

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.